DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2017-07-27
Target enrollment:
Participant gender:
Summary
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to
carry cancer killing substances directly to the cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of DT388IL3 fusion
protein and to see how well it works in treating patients with acute myeloid leukemia or
myelodysplastic syndromes.